Article
Incident or worsening colitis is a rare complication of IL-17 inhibitor therapy; a real world study confirms very low rates of new IBD in patients starting secukinumab.
All News
Article
Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul
Dr. John Cush
Tweet
News Feature: Low IBD Risk with IL-17 Inhibition
https://t.co/1kUH7sP755 https://t.co/DypPAcxB2a
Dr. John Cush
Tweet
Data Safety committee has closed recruitment to the colchicine arm in the RECOVERY trial a UK study of outcomes in COVID-19. Among 11162 enrolled pts (2178 deaths) those Rx w/ Colchicine had same 28 day mortality as usual care (20% vs. 19%) https://t.co/8gUc8LAZTp
Dr. John Cush
Tweet
Not surprisingly, a trial of repetitive transcranial magnetic stimulation failed to improve pain in fibromyalgia - next we can look forward to eye of newt N-of-1 trials. https://t.co/mEvvZhYgyR
Dr. John Cush
Tweet
We are just two weeks out from RheumNow Live. There's still time to register. Attend virtually or in-person. CME credits available.
https://t.co/3zMtzt4t2H https://t.co/09Q5rRXsst
Dr. John Cush
Tweet
RheumNow Podcast – Pounds of Prevention
Dr. Jack Cush Reviews the news and journal reports from the past week on RheumNow. This podcast is sponsored by RheumNow Live.
https://t.co/4XSBysiVFW https://t.co/PREqOkyuM9
Dr. John Cush
Tweet
Population study from Southern Norway shows the incidence of giant cell arteritis is not increasing. Over 13yrs, from pop of 300k they identified 206 GCA pts (72%females). Incidence rate of 16.8/100k per year. Mortality was not increased https://t.co/UA16uIuwD1
Dr. John Cush
Tweet
QD Clinic - RA and LFTs
NAFLD, NASH and Risks with DMARDs and MTX
https://t.co/LYV9WycEjz https://t.co/CMGtU4vclY
Dr. John Cush
Tweet
#RA associated interstifial lung dz has incidence of 1-5 per 1,000 PYs and prevalence as high as 67%; risk factors; age, male sex, Dz duration, CCP Abs; w/ age as best predictor of mortality. There is no clear drug interventions that helps RA-ILD https://t.co/zJvWqt0w6L
Dr. John Cush
Tweet
RheumNow Live is a powerful, interactive meeting delivered by researchers, educators, & clinicians.
Sign up to attend virtually or in-person today.
https://t.co/SvLpwNYh9c
Dr. John Cush
Tweet
Why it's safe to come to RheumNow Live. Lessons learned from restaurants and flying.
https://t.co/R0eYO2GiPd https://t.co/E9vPjzUTgb
Dr. John Cush
Tweet
News Feature: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease
https://t.co/6A4muejeH9 https://t.co/xQbIoEEscv
Dr. John Cush
Tweet
Download available--Difficult RA Defined
https://t.co/6WGMEiwiUk
Dr. John Cush
Tweet
RheumNow podcast now available! Listen on SoundCloud and Apple/Android podcasts.
https://t.co/P6kaqZP0PJ https://t.co/BPQ5Ey7d0r
Dr. John Cush
Tweet
"... think what others won’t think;
go where others won’t go;
do what others won’t do;
and be what others want to be."
- Phil knight
Dr. John Cush
Tweet
News Feature: Baricitinib Therapy in Covid-19 Pneumonia
https://t.co/b3tsLcoXay https://t.co/tjqkk1RLFZ
Dr. John Cush
Tweet
Download available--Arthritis Myths
https://t.co/2Kxpou4Fbz
Dr. John Cush
Tweet
We have a robust agenda planned for RheumNow Live. Have you registered yet?
https://t.co/3zMtzt4t2H https://t.co/iLNj8XEu4X
Dr. John Cush
Tweet
QD Clinic - Remission Time
What to do when not quite in remission
https://t.co/BjALXBPVYm https://t.co/HftUANlU1b
